Merck KGaA, Novo Nordisk and Insulet Corporation are Dominating the Global Electronic Drug Delivery Systems Market in 2019

Global Electronic Drug Delivery Systems Market is expected to grow with the CAGR of 8.9% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/global-electronic-drug-delivery-systems-market

Global electronic drug delivery systems market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.     

The major players dealing in global electronic drug delivery systems market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance, In December, 2019 Insulet Corporation has launched Omnipod DASH System in Netherlands and U.K., which is provides upto three days of non- stop insulin delivery without using any injection. This product launch helped the company to enhance its product portfolio for electronic drug delivery systems, which had a positive impact on revenue.

Merck KGaA is the dominating player in global electronic drug delivery systems market. The other key players existing in the market includes AstraZeneca, Amgen Inc., Ypsomed AG, Bayer AG, Nemera, F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), AptarGroup, Inc., Novo Nordisk A/S., ViCentra B.V., Medtronic, United Therapeutics Corporation, Companion Medical, Tandem Diabetes Care, Debiotech S.A., Canè SpA, Insulet Corporation, BD, Findair Sp. z o. o. , B. Braun Melsungen AG , West Pharmaceutical Services, Inc. among others.

Electronic Drug Delivery Systems MarketMerck KGaA

Merck KGaA headquartered is in Darmstadt, Germany was founded in 1668. The company is engaged in providing solutions in the field of healthcare, life science and performance materials with a passion for technology and love for science. The company has multiple business segments including display solutions, semiconductor solutions, surface solutions, other. In this other is market focused segment. The company also has wide product portfolio such as endocrinology, neurology & immunology, general medicine, oncology, fertility, in which endocrinology, neurology are the market focused category.   

  • In October 2017, Merck announced positive result from use of easypod in children with growth disorder, which suggested the high adherence level to growth hormone on its administration via easypod. This data helped the company to enhance its product sales by helping doctors and physicians to get a perfect product for drug administration.

The company has wide presence across Africa, Asia, Europe, Latin America, North America, Oceania. The company also has various subsidiary companies such as Sigma-Aldrich (OM) Ltd.(Greece), Merck Foundation gGmbH(Germany), Merck S.A.(Venezuela),iOnctura SA(Switzerland), Merck Ltd.(U.K), Fluka Chemical Corp.(U.S.), among others.

Novo Nordisk

Novo Nordisk headquartered in Bagsvaerd, Denmark was founded in 1923. The company focuses to drive change so as to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.the company has wide product portfolio including diabetes, obesity, haemophilia, human growth hormone, hormone replacement therapy, in which diabetes, human growth hormone are the market focused product category.

  • In February 2019, Abbott entered into partnership with Novo Nordisk in order to integrate insulin dose data from Novo Nordisk prefilled and durable connected pens into the digital heath tools. This partnership helped the company to enhance its plat for for diabetes management.

The company has wide presence across Europe, Americas, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such as Novo Nordisk Canada Inc., (Canada), Novo Nordisk US Bio Production, Inc., (U.S.), Novo Nordisk Pharma GmbH (Austria), Novo Nordisk Region Europe Pharmaceuticals A/S, (Denmark) among others.

Insulet Corporation

Insulet Corporation headquartered in Massachusetts, U.S. was founded in 2000. The company is engaged in providing innovative medical device dedicated to making the lives of people with diabetes and other conditions easier by using the omnipod product platform, which is a unique platform for insulin delivery. The company is providing omnipod system, omnipod dash system which is the market focused product category.

  • In October 2019, Insulet Corporation received FDA clearance for Fiasp (fast-acting insulin aspart) for use with the Omnipod DASH Insulin Management System and Omnipod Insulin Management System. Fiasp developed by Novo Nordisk is ultra-fast acting insulin.  This clearance helped the company to expand the usage of Ominpod, by product expansion company can enhance product sales.

The company has wide presence across Europe, Canada, Israel. The company also has various subsidiary companies such as Insulet Canada Corporation (Canada), Sub Q Solutions Inc.(Delaware), Insulet Singapore Private Limited(Singapore), Insulet Austria GmbH(Austria), Insulet Netherlands B.V( Netherlands) among others.